Skip to main content

Hematology and Oncology

ALL Specialities ALL Specialities

/

Hematology and Oncology

Blood & Cancer Podcast
CME
Diseases & Conditions
- Nonmalignant Hematologic Disorders
- Breast Cancer
- CNS/Brain Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
  - Renal Cell Carcinoma
- Gynecologic Cancer
- Head & Neck/Thyroid Cancers
- Leukemia, Myelodysplasia, Transplantation
  - ALL
  - AML
  - Cellular Therapy
  - CLL
  - CML
  - Myelodysplastic Syndrome
  - Transplantation
- Lung Cancer
- Lymphoma & Plasma Cell Disorders
- Melanoma
- Nonmelanoma Skin Cancer
- Sarcoma and GIST
COVID-19 Updates
Conference Coverage

News

FDA Approves Pertuzumab for Metastatic HER2+ Breast Cancer

Publish date: June 11, 2012

* This story was updated on 11/30/2012.

Pages

« first
1
2

Recommended Reading

Docs Need Primer on Long-Term Effects of Chemotherapy

MDedge Hematology and Oncology

Cancer Trial Groups ECOG and ACRIN Complete Merger

MDedge Hematology and Oncology

T-DM1 Tops Capecitabine-Lapatinib in Advanced HER2-Positive Breast Cancer

MDedge Hematology and Oncology

Hodgkin's Survivors Face High Breast Cancer Risk

MDedge Hematology and Oncology

Paclitaxel Matches New Drugs as First-Line Breast Cancer Therapy

MDedge Hematology and Oncology

Duloxetine Eases Pain of Chemo-Induced Neuropathy

MDedge Hematology and Oncology

'Doing Just Fine, Thanks'

MDedge Hematology and Oncology

Less Zoledronic Acid May Work in Breast Cancer

MDedge Hematology and Oncology

SLN-Negative Breast Cancer Has Low Regional Recurrence

MDedge Hematology and Oncology

Cancer recurrence and survival in patients with early-stage triple-negative breast cancer

MDedge Hematology and Oncology

Related Articles

News

Dual HER2 Blockade Defers Breast Cancer Progression

Author:

Doug Brunk

Publish date: December 7, 2011

Major Finding: Adding pertuzumab to a standard chemotherapy regimen of trastuzumab and docetaxel led to an additional 6 months of progression-free...
- Read More
News

Dual HER2 Blockade Strategies Advance in Breast Cancer Trials

Author:

Patrice Wendling

Publish date: August 9, 2011
- Read More

Breast Cancer

This Publication

About Us
Advertise
Contact Us
Corporate Management
Customer Service

Specialty Focus

Bleeding Disorders
Breast Cancer
CLL
CML
Genitourinary Cancer
Indolent Lymphoma
Leukemia, Myelodysplasia, Transplantation
Lung Cancer
Multiple Myeloma
Sarcoma & GIST

Top Sections

Commentary
Medical Education Library
Best Practices

Highlighted from this site and network

Contact MD-IQ
Contact ClinicalEdge

Editorial Policy

Medscape Customer Support

Frequently Asked Questions

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

All Specialties